{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The effect on bone mineral density（BMD） will be measured by quantitative analysis of qCT scans of the intra-individual same region \\[lumbar spine and hip\\] at baseline, on day 28 of cycles 4, and after 4, 6, 12 and 18 months of follow-up or until start of alternative MM treatment, if earlier.","groups":[{"description":"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.\n\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.\n\nPAD Followed by ASCT: Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)\n\nDrug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)\n\nDrug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)\n\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.","id":"OG000","title":"PAD Followed by ASCT"}],"populationDescription":"Data were not collected.","reportingStatus":"POSTED","timeFrame":"At baseline, on day 28 of cycles 1,4, and after 4, 6, 12 and 18 months of follow-up or until start of alternative MM treatment","title":"Measurement of Bone Mineral Density","type":"SECONDARY"}